Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 10—October 2020
Research

Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017

Reiko Shimbashi, Motoi SuzukiComments to Author , Bin Chang, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Kengo Oshima, Takaya Maruyama, Hiroaki Takeda, Kei Kasahara, Jiro Fujita, Junichiro Nishi, Tetsuya Kubota, Keiko Tanaka-Taya, Tamano Matsui, Tomimasa Sunagawa, Kazunori Oishi, and Adult IPD Study Group
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (R. Shimbashi, M. Suzuki, B. Chang, K. Tanaka-Taya, T. Matsui, T. Sunagawa, K. Oishi); Tohoku University Graduate School of Medicine, Miyagi, Japan (R. Shimbashi, M. Suzuki, K. Oshima); Kurume University School of Medicine, Fukuoka, Japan (H. Watanabe); Niigata Prefectural Shibata Hospital, Niigata, Japan (Y. Tanabe); Sapporo Medical University School of Medicine, Hokkaido, Japan (K. Kuronuma); National Hospital Organization Mie National Hospital, Mie, Japan (T. Maruyama); Yamagata Saisei Hospital, Yamagata, Japan (H. Takeda); Nara Medical University, Nara, Japan (K. Kasahara); Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan (J. Fujita); Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (J. Nishi); Kochi Medical School, Kochi University, Kochi, Japan (T. Kubota); Toyama Institute of Health, Toyama, Japan (K. Oishi)

Main Article

Table 4

Stratified analyses of the effectiveness of PPSV23 against invasive pneumococcal disease in adults >20 years of age, Japan, 2013–2017*

Characteristic No. cases No. controls Crude VE, % (95% CI) Adjusted VE,† % (95% CI) p value
Sex
M 443 236 41.5 (2.0 to 65.0) 38.7 (−5.1 to 64.3) 0.917
F
 303
 139
 52.7 (2.5 to 77.1)
 48.5 (5.3 to 72.0)
Age group, y
20–64 245 119 72.5 (13.6 to 91.3) 59.0 (17.9 to 79.6) 0.170
>65
 501
 256
 41.7 (7.2 to 63.3)
 39.2 (2.0 to 62.2)
Clinical manifestations
Pneumonia 480 185 55.8 (26.2 to 73.5) 50.6 (16.0 to 70.9) 0.284
Meningitis 94 75 46.9 (−76.6 to 84.1) 35.6 (−100.0 to 79.2)
Bacteremia 104 84 41.8 (−78.2 to 81.0) 34.7 (−72.1 to 75.2)
Other‡
 68
 30
 NA
 NA
BMI group, kg/m2
<18.5 171 86 11.3 (−109.4 to 62.4) 7.4 (−108.1 to 58.8) 0.005
18.5–24.9 346 180 73.2 (50.8 to 85.4) 70.6 (47.7 to 83.5)
>25
 111
 56
 −133.3 (−765.0 to 37.1)
 −136.5 (−826.6 to 39.6)
Underlying conditions
Immunocompromised 175 139 41.0 (−22.0 to 71.4) 41.2 (−27.6 to 72.9) 0.971
Other condition 324 155 48.5 (7.2 to 71.4) 48.2 (6.0 to 71.5)
No underlying condition 198 58 48.8 (−113.3 to 87.7) 51.5 (−116.0 to 89.1)

*BMI, body mass index; NA, not available; PPSV23, 23-valent pneumococcal polysaccharide vaccine; VE, vaccine effectiveness.
†Adjusted for sex, age, prefecture, year, season, BMI group, underlying conditions, and smoking history with clustering by public health center.
‡Includes arthritis, endocarditis, sinusitis, otitis media, vertebritis, cholecystitis, aortic aneurysm, and pleurisy.

Main Article

Page created: August 05, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external